

**GORE® CARDIOFORM**  
Septal Occluder



# TOP 5 REASONS TO CHOOSE **GORE® CARDIOFORM** SEPTAL OCCLUDER

The GORE® CARDIOFORM Septal Occluder advances patent foramen ovale (PFO) closure with a solution designed to naturally conform to a patient's unique PFO anatomy\* — delivering on long-term safety and performance.<sup>1</sup>

\*All PFO anatomies within indicated sizing parameters of the *Instructions for Use* (IFU).

*Together, improving life*





## Advanced Materials Delivering Exceptional Conformability<sup>\*,†,‡,§,1-3</sup>

Engineered to conform to a broad range of PFO anatomies.<sup>§,1-3</sup>

1

- **ePTFE** – Biocompatible, compliant material enables exceptional conformability and rapid tissue ingrowth.
- **Two independent discs and five independent petals** – Allow the device to conform to the anatomy to treat simple to complex defects.
- **Minimal metal** – Designed to reduce the risk of tissue damage. Minimal nickel elution and exposure relative to other competitive nitinol-framed devices.<sup>¶,¶,4</sup>

## A Leader in Safety

Long-term results continue to demonstrate a legacy of patient safety.

2

68,000+  
devices sold globally

0

reported cardiac erosions\*\*



\* 99% effective closure rate across PFO anatomies at 24 months.

† Effective closure defined as freedom from large shunt > 25 bubbles as detected by transthoracic echocardiography adjudicated by Echo Core Lab.

‡ Data on file 2020; W. L. Gore & Associates, Inc.; Flagstaff, AZ.

§ All PFO anatomies were eligible for inclusion into this study within indicated sizing parameters of the *Instructions for Use*.

¶ Patients allergic to nickel may suffer an allergic reaction to the GORE® CARDIOFORM Septal Occluder device. Certain allergic reactions can be serious; patients should be instructed to notify their physicians immediately if they suspect they are experiencing an allergic reaction such as difficulty in breathing or inflammation of the face or throat. Some patients may also develop an allergy to nickel if this device is implanted. Refer to the *Instructions for Use* for complete device information, including contraindications, warnings and cautions.

¶¶ As characterized by an in vitro assessment.

\*\* Reported incidence rate of device-related cardiac erosions for GORE® CARDIOFORM Septal Occluder. Data from CATSWeb Product Surveillance Tracking System (PSTS). June, 2011–January, 2023. W. L. Gore & Associates, Inc.; Flagstaff, AZ.

## Trusted Closure Performance

Engineered to conform to a broad range of PFO anatomies<sup>\*,1-3</sup> — simple to complex.

99% effective closure across PFO anatomies at 24 months<sup>†,‡</sup>

## Complex PFO: Atrial Septal Aneurysm (ASA)



**Image A:** ICE demonstrating PFO with ASA.



**Image B:** Closure of PFO with 30mm GORE® CARDIOFORM Septal Occluder.

## Clinically Proven Secondary Stroke Prevention<sup>§,||,¶,1,2</sup>

4 Backed by the only U.S. IDE trial that achieved its primary endpoint, and over five years showed a significant reduction in recurrent stroke across PFO anatomies over medical therapy alone.<sup>§,||,¶</sup>

69% relative reduction in recurrent stroke versus medical management alone at 5-year median follow-up<sup>||,1</sup>

## Reliable and Safe Delivery

5 Straightforward delivery with the ability to reposition and retrieve.\*\*

Pre-assembled Occluder and delivery system designed to reduce device preparation time.

\*All PFO anatomies within indicated sizing parameters of the *Instructions for Use* (IFU).

† Effective closure defined as freedom from large shunt > 25 bubbles as detected by transthoracic echocardiography adjudicated by Echo Core Lab.


‡ Data on file 2020; W. L. Gore & Associates, Inc.; Flagstaff, AZ.

§ In patients with a PFO and history of cryptogenic stroke.

|| The REDUCE Study determined safety and efficacy of PFO closure with the GORE® CARDIOFORM Septal Occluder or GORE® HELEX® Septal Occluder plus antiplatelet medical management compared to antiplatelet medical management alone in patients with a PFO and history of cryptogenic stroke. All PFO anatomies were eligible for inclusion into this study within indicated sizing parameters of the *Instructions for Use*.

¶ REDUCE is the only U.S. IDE trial that achieved its primary endpoint, and over five years showed a significant reduction in recurrent ischemic stroke across PFO anatomies over medical therapy alone.

\*\* Refer to *Instructions for Use* at [eifu.goremmedical.com](http://eifu.goremmedical.com) for all applicable indications, warnings, precautions and contraindications for the markets where this product is available.



## Device Specifications

Labeled Occluder diameter	Maximum recommended defect size measured with stop flow balloon sizing	Catheter size without guidewire <sup>†</sup>
20 mm	11 mm	10 Fr
25 mm	14 mm	10 Fr
30 mm	17 mm	10 Fr

To learn more about the device that is designed to naturally conform to a patient's unique PFO anatomy<sup>†</sup>, contact your Gore Representative.

\* Recommendation for sheath size is 2 Fr larger when used with a wire.  
† All PFO anatomies within indicated sizing parameters of the *Instructions for Use* (IFU).

## References

1. Kasner SE, Rhodes JF, Andersen G; Gore REDUCE Clinical Study Investigators. Five-year outcomes of PFO closure or antiplatelet therapy for cryptogenic stroke. *New England Journal of Medicine* 2021;384(10):970-971.
2. Søndergaard L, Kasner SE, Rhodes JF, et al.; Gore REDUCE Study Investigators. PFO closure or antiplatelet therapy for cryptogenic stroke. *New England Journal of Medicine* 2017;377(11):1033-1042.
3. Lefebvre B, Naidu S, Nathan AS, et al. Impact of echocardiographic parameters on recurrent stroke in the randomized REDUCE PFO cryptogenic stroke trial. *Structural Heart* 2021;5(4):367-375.
4. Verma DR, Khan MF, Tandar A, et al. Nickel elution properties of contemporary interatrial shunt closure devices. *Hours of Invasive Cardiology* 2015;27: 99-104.

 Consult Instructions for Use  
[eifu.goremedical.com](http://eifu.goremedical.com)

Refer to *Instructions for Use* at [eifu.goremedical.com](http://eifu.goremedical.com) for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only

Products listed may not be available in all markets.

GORE, *Together, improving life*, CARDIOFORM, HELEX and designs are trademarks of W. L. Gore & Associates.  
© 2023 W. L. Gore & Associates GmbH 231056856-EN SEPTEMBER 2023

W. L. Gore & Associates, Inc.  
[goremedical.com](http://goremedical.com)

Asia Pacific +65 6733 2882 Australia/New Zealand 1800 680 424 Europe 00800 6334 4673  
United States Flagstaff, AZ 86004 800 437 8181 928 779 2771

